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Background: Metastasis is the most crucial prognostic factor in osteosarcoma. The goal of this study was to
develop a new nomogram to predict the probability of metastasis in Enneking stage IIB extremity osteosarcoma
after neoadjuvant chemotherapy and limb salvage surgery.
Methods: We examined medical records of 91 patients who had undergone surgery between March 1994 and
March 2007. A nomogram was developed using multivariate logistic regression. The nomogram was validated
internally by bootstrapping-method (200 repetitions) and externally in independent validation set (n = 34). A
Youden-derived cutoff value was assigned to the nomogram to predict dichotomous outcomes for metastasis.
Results: The nomogram was built from four predictors of tumor site, serum alkaline phosphatase, intracapsular
extension, and Huvos grade, and an additional clause that the cutoff value should be added to the total points in
the cases of incomplete surgical resection. P-value of Hosmer and Lemshow Goodness-of-fit test of this model was
0.649. Area under receiver operating curve values of 0.83 (95% confidence interval [CI], 0.75 to 0.92) in the training
set and 0.80 (95% CI, 0.63 to 0.96) in the validation set were obtained. The accuracy of dichotomous outcomes was
79.1% (95% CI, 0.69 to 0.86) and 82.4% (95% CI, 0.63 to 0.92) in the training and validation sets.
Conclusions: We have developed a new high-performance nomogram to predict the probability of metastasis in
Enneking stage IIB extremity osteosarcoma after limb salvage surgery.
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Although osteosarcoma is a rare disease, it is the most
common primary malignant bone tumor. Prior to 1970,
the oncologic outcomes of osteosarcoma were extremely
poor with only a 10-20% overall survival rate despite
aggressive surgery. The overall survival rates of osteosar-
coma have dramatically increased to approximately 65-75%
with the establishment of multidisciplinary treatments [1].
The Enneking staging system and American Joint
Committee on Cancer (AJCC) are used to classify
osteosarcoma according to prognosis primarily based
on histologic grade and metastasis at diagnosis [2,3]. In* Correspondence: QSHIN@yuhs.ac
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unless otherwise stated.addition to the factors used for clinical staging, many
other clinical factors have been reported to be prog-
nostic factors for osteosarcoma such as age, [4] tumor
location, [5-7] serum markers such as alkaline phos-
phatase (ALP) [8] and lactate dehydrogenase (LDH),
[9] pathologic fracture, [10] histologic type, [11] and
histologic response to neoadjuvant chemotherapy [12].
Molecular markers of prognosis in osteosarcoma have
also been reported including ezrin, chemokine recep-
tor 4, and P-glycoprotein [13]. Because no single factor
can accurately predict prognosis, statistical prediction
models to integrate the cumulative effects of individual
prognostic factors are required for more precise prog-
nosis predictions. Nomograms have been proposed as
a new and alternative tool to traditional staging sys-
tems for predicting prognosis in a variety of cancers. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sue sarcoma [15,16] and osteosarcoma [17].
Although multidisciplinary approach has dramatically
improved survival in osteosarcoma, the presence of
metastasis makes this a challenging disease to cure, for
survival rates of osteosarcoma with metastasis are of ap-
proximately 20% [18]. On the other hand, osteosarcoma
without metastasis can be cured and most osteosarcoma
patients without metastasis live a long and healthy life.
Therefore, the accurate prediction of an individual pa-
tient’s probability of metastasis is important. The pur-
pose of this study was to develop a new nomogram to
predict the probability of metastasis in Enneking stage
IIB extremity osteosarcomas, which rank the majority of
osteosarcoma cases.
Methods
Patients
We searched and retrospectively reviewed the medical
records of Enneking stage IIB extremity osteosarcoma
patients who had undergone surgery between March
1994 and March 2007 (cohort 1) at Severance HospitalFigure 1 Diagram for populations of training and validation set. Coho
have surgery between March 1994 and March 2007 at Severance Hospital
osteosarcoma who had have surgery between April 2007 and March 2011
malignant neoplasm, mets, metastasis, F/U, follow up.(Seoul, Korea). This study was done under Severance
Hospital Institutional Review Board-approved protocol.
We restricted the inclusion criteria for the training set
to the patients who had undergone standard therapy
(neoadjuvant chemotherapy, definitive surgery, and adju-
vant chemotherapy) and limb salvage surgery that was
performed by the same surgeon. Of the 140 patients
identified, 108 patients were enrolled in the study. Of
the 108 patients, 91 and 17 patients were included in the
training and validation sets, respectively, according to
the inclusion criteria. An additional 17 patients who had
undergone surgery between April 2007 and July 2011
(cohort 2) at Severance Hospital were included in the
validation set (Figure 1). The clinical characteristics of
the training and validation sets are listed in Table 1. The
overall 5-year survival rate of the training set was 70.3%.
The proportions of patients with metastasis in the train-
ing and validation sets were 37.4% and 50%, respectively.
Because the follow-up period of cohort 2 (with the longest
follow-up period of 7 years) was much shorter than that of
cohort 1 (with the longest follow-up period of 19 years),
fewer patients with 5-year continuously disease free (CDF)rt 1 included the patients with Enneking IIB osteosarcoma who had
(Seoul, Korea) and Cohort 2 included the patients with Enneking IIB
at the same institute. LSS, limb salvage surgery, SMN, secondary
Table 1 Clinical characteristics of training and validation sets
Variables Training (N=91) Validation (N=34)
N % N %
Survival 5 years survivor (CDF from definitive surgery) 58 63.7 16 47.1
5 years survivor (NED after metastasectomy) 6 6.6 2 5.9
DOD 27 29.7 7 20.6
NED (after metastasectomy) < 5 years 0 0.0 6 17.6
AWD 0 0.0 2 5.9
DOC 0 0.0 1 2.9
Metastasis Positive 34 37.4 17 50.0
Free 57 62.6 17 50.0
Sex Male 50 54.9 19 55.9
Female 41 45.1 15 44.1
Age ≤ 14 yrs 36 39.6 17 50.0
> 15 yrs 55 60.4 17 50.0
Tumor site Distal femur 46 50.5 12 35.3
Proximal tibia 17 18.7 7 20.6
Proximal humerus 14 15.4 5 14.7
Others 14 15.4 10 29.4
Tumor size ≥ 8cm 62 68.1 20 58.8
< 8cm 29 31.9 14 41.2
Pathologic fx at diagnosis Yes 5 5.5 2 5.9
No 86 94.5 32 94.1
Skip lesion Yes 3 3.3 2 5.9
No 88 96.7 32 94.1
Intracapsular extension Yes 20 22.0 10 29.4
No 71 78.0 24 70.6
ALP Elevation 56 61.5 11 32.4
Normal 35 38.5 23 67.6
LDH Elevation 9 9.9 5 14.7
Normal 53 58.2 16 47.1
NA 29 31.9 13 38.2
Histologic type Osteoblastic 62 68.1 17 50.0
Chondroblastic 11 12.1 3 8.8
Fibroblastic 4 4.4 1 2.9
Mixed 12 13.2 5 14.7
Others 2 2.2 3 8.8
NA 0 0.0 5 14.7
Huvos grade III and IV 65 71.4 21 61.8
I and II 26 28.6 13 38.2
Operation Type Limb salvage surgery 91 100.0 23 67.6
Amputation 0 0.0 11 32.4
Surgeon factor Surgeon 1 91 100.0 22 64.7
Surgeon 2 0 0.0 10 29.4
Surgeon 3 0 0.0 2 5.9
Surgical resection R0 85 93.4 33 97.1
R1 6 6.6 1 2.9
Abbreviation: CDF, continuously disease free, DOD, died of disease, NED, no evidence of disease, AWD, alive with metastatic disease, DOC, died of other cause, fx,
fracture, ALP, alkaline phosphatase, LDH, lactate dehydrogenase, NA, not available.
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ease (NED) status after last metastasectomy were enrolled
in cohort 2 than cohort 1, which led to quite a difference in
the proportions of patients with metastasis.
No patients received radiation therapy at the primary
tumor site. Only seven patients in the training set
received palliative radiation therapy on the metastatic
lesions. All the patients received neoadjuvant chemo-
therapy. Sixty-five patients were treated with doublet of
intra-arterial cisplatin (DDP) and doxorubicin (ADR), fifty
patients were treated with triplet intra-arterial DDP, ADR,
and ifosafamide (Ifos). Ten patients were treated with other
regimens: five patients with ADR and intravenous DDP;
four patients with ADR, intravenous DDP, and methotrex-
ate (MTX); and one patient with VP-16, Ifos, and MTX.
Huvos grade, disease-free survival, and overall survival wereTable 2 χ2 tests for identification of prognostic factors for m
Candidate
Sex Male
Female
Age ≤ 14 years
> 15 years
Tumor site Distal femur/Proximal tibia/Proximal hum
(Not exceeding the isthmus)
Others
Laterality Left
Right
Tumor size ≥ 8 cm
< 8 cm
Pathologic fracture at diagnosis Yes
No
Skip lesion Yes
No
Intracapsular extension Yes
No
ALP at diagnosis Elevated
Normal
LDH at diagnosis Elevated
Normal
Histologic type Osteoblastic/chondroblastic/fibroblastic
Others (mixed and nonconventional typ
Limb salvage surgery type Without Pasteurization
With Pasteurization
Huvos grade I & II
III & IV
Surgical resection Complete
Incomplete
Abbreviation: ALP alkaline phosphatase, LDH lactate dehydrogenase.
*Calculated using Fisher’s extract test.not significantly different between doublet and triplet regi-
mens in our cohorts [19].
Developing the nomogram
We identified candidate predictors of metastasis using
the χ2 test and performed multivariate analysis of a var-
iety of suggested candidates (Table 2). Among these can-
didates, we chose the parameters for a nomogram that
were statistically significant and developed a weighted
nomogram. The association between these parameters
and metastasis was evaluated using multivariate logistic
regression analysis. A nomogram was developed on the
basis of the multivariate logistic regression model using
tumor site, ALP at diagnosis, intracapsular extension,
and Huvos grade. The goodness-of-fit of the nomogram
was calculated using the Hosmer-Lemeshow test.etastasis
Metastasis positive (%) Metastasis free (%) P
21 (42.0) 29 (58.0) 0.31
13 (31.7) 28 (68.3)
12 (33.3) 24 (66.7) 0.52
22 (40.0) 33 (60.0)
erus 12 (21.1) 45 (78.9) <0.001
22 (67.4) 12 (35.3)
13 (32.5) 27 (67.5) 0.40
21 (41.2) 30 (58.8)
25 (40.3) 37 (59.7) 0.39
9 (31.0) 20 (69.0)
3 (60.0) 2 (40.0) 0.36*
31 (36.0) 55 (64.0)
2 (66.7) 1 (33.3) 0.55*
32 (36.4) 56 (63.6)
13 (65.0) 7 (35.0) 0.004
21 (29.6) 50 (70.4)
26 (46.4) 30 (53.6) 0.02
8 (22.9) 27 (77.1)
5 (55.6) 4 (44.4) 0.12*
14 (26.4) 39 (73.6)
19 (29.2) 46 (70.8) 0.02
e) 9 (60.0) 6 (40.0)
28 (36.4) 49 (63.6) 0.64
6 (42.9) 8 (57.1)
15 (57.7) 11 (42.3) 0.01
19 (29.2) 46 (70.8)
28 (32.9) 57 (67.1) 0.002*
6 (100.0) 0 (0.0)
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the nomogram
The parameters of all predictors were divided into two
prognosis groups, good or poor.
Tumor site
Tumors located along the distal femur, proximal tibia, and
proximal humerus were regarded as the good prognosis
group and those at other locations were regarded as the
poor prognosis group. In addition, tumors along the distal
femur, proximal tibia, and proximal humerus with a longi-
tudinal size that it exceeded the isthmus of the affected
bone (more than half the entire length of the affected bone)
were categorized in the poor prognostic group.
Intracapsular extension
Intracapsular extension was regarded as the poor prog-
nosis group. Intracapsular extension of the tumor was
defined not only as direct penetration of the articular
cartilage but also as the involvement of intracapsular
and extrasynovial structures. Diagnosis of intracapsular
extension by MRI, whether positive or negative, was
confirmed by gross pathology.
Serum ALP levels at diagnosis
Normal level of alkaline phosphatase (ALP) was regarded
as the good prognosis group. The serum ALP levels
were measured in international units (IU), and the
activity of ALP was estimated by the p-nitrophenyl
phosphate method. ALP ranges of 60.0-300.0 IU/L for
patients ≤14 years and 38.0-115.5 IU/L for patients >
15 years were considered normal.
Response to neoadjuvant chemotherapy
Responses to neoadjuvant chemotherapy were graded on
the basis of the amount of tumor necrosis in the resected
specimen. More than 90% tumor necrosis was regarded as
a good response; a cut-off of 90% tumor necrosis is usually
used to distinguish good and poor responders. Good re-
sponse was categorized in the good prognosis group.Table 3 RR and OR of prognostic factors for metastasis
RR (95% CI) Uni
OR (95%
Constant
Tumor site 3.07 (1.75 to 5.38) 6.88 (2.66 to
ALP at diagnosis 2.03 (1.04 to 3.97) 2.93 (1.13 t
Intracapsular extension 2.20 (1.36 to 3.56) 4.42 (1.55 to
Huvos grade 1.97 (1.20 to 3.26) 3.30 (1.29 t
Histologic type 2.05 (1.17 to 3.59) 3.74 (1.14 to
Surgical resection 3.04 (2.24 to 4.11) NA
Abbreviation: RR relative risk, OR odds ratio, CI confidential interval, ALP alkaline pho
fit test is 0.649.Surgical resection
Surgical resection was assessed by resection margin from
pathology not surgical margin. Free of tumor (R0) was
defined as complete surgical resection, while positive
margins microscopically (R1) and macroscopically (R2)
were defined as incomplete surgical resection. Complete
surgical resection was regarded as good prognosis group.
Statistical analysis
The performance of our nomogram was evaluated in-
ternally and externally for discrimination and calibration.
Discrimination was evaluated by the area under receiver
operating characteristic curve (AUC) for both the training
set (N = 91) and the external validation set (N = 34). A 95%
confidence interval (CI) was calculated for each AUC.
Calibration plots were obtained from bootstrapping (200
repetitions) of the training and validation sets.
To improve the clinical practicality of the nomogram,
we assigned a cutoff value, derived from the Youden
index, to the nomogram to allow for the prediction of
dichotomous outcomes for metastasis. Nomogram per-
formance in predicting dichotomous outcomes was also
evaluated in the training and validation sets by two-way
contingency table analysis. A 95% CI was calculated for
each indicator.
All statistical analysis were performed using SPSS (ver-
sion 20.0, SPSS, Inc., Chicago, IL, USA), SAS (version 9.2,
SAS Institute Inc., Cary, NC, USA), and R (version 2.9.1,
The R Foundation for Statistical Computing, Vienna,
Austria). All P values were two-tailed, and a P value < 0 .05
was considered significant.
Results
Nomogram development and validation
Six factors of tumor site, ALP level at diagnosis, intra-
capsular extension, Huvos grade, histologic type, and
surgical resection were identified as prognostic factors
for metastasis (Table 2). The odds ratios for metastasis
were calculated for these and are shown in Table 3. The
odds ratio of surgical resection was beyond compute,variate analysis Multivariate analysis*
CI) P OR (95% CI) P
0.00 0.000
17.76) 0.000 6.49 (2.13 to 19.78) 0.001
o 7.55) 0.03 4.27 (1.34 to 13.64) 0.01
12.65) 0.006 5.19 (1.47 to 18.27) 0.01
o 8.49) 0.01 2.37 (0.73 to 7.67) 0.15
12.34) 0.03
NA
sphatase, NA not applicable. * P-value of Hosmer and Lemshow Goodness-of-
Kim et al. BMC Cancer 2014, 14:666 Page 6 of 10
http://www.biomedcentral.com/1471-2407/14/666because all the cases with incomplete surgical resection
had undergone metastasis. Huvos grade and histologic
type were strongly correlated and confounded the multi-
variate analysis. Therefore, surgical resection and histo-
logic type were excluded from the prediction model. On
the basis of multivariate logistic regression analysis, we
built a nomogram using tumor site, ALP level at diagno-
sis, intracapsular extension, and Huvos grade as the
predictors (Figure 2A). The P value of the Hosmer-Figure 2 Nomogram to predict probability of metastasis and validatio
set of 91 patients (C) ROC curve for the validation set of 34 patients (D) ca
set. ROC curve, receiver operating characteristic curve.Lemeshow test for the prediction model was 0.65, which
indicated the good statistical fit of the model.
AUC values of 0.83 (95% CI, 0.75 to 0.92) and 0.80
(95% CI, 0.63 to 0.96) were obtained in the training and
validation sets, respectively (Figure 2B and C). The
calibration plot for the training and validation sets is
shown in Figure 2D and E, respectively. The bootstrap-
corrected AUC was 0.81. There was no significant differ-
ence among the three AUC values, which suggested thatns. (A) The postoperative monogram (B) ROC curve for the training
libration plot for the training set (E) calibration plot for the validation
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cible in other populations. The calibration plots showed
that the nomogram predicted probabilities were slightly
lower than the actual probabilities.
Cutoff value for dichotomous outcomes
Nomograms show the probability of metastasis as a per-
centage; however, dichotomous outcomes for metastasis
are likely to be a user friendly option in practice. Therefore,
we assigned a Youden-derived cutoff value to the nomo-
gram. The cutoff value was a total of 123 points, which
was equal to a predicted probability of 0.36. The combined
score of the two poor prognosis parameters with the lowest
scores was more than the cutoff value. Therefore, the di-
chotomous decision for metastasis is positive whenever
any two of the four predictors are classified as poor group.
The relative risk comparisons for the predictors
showed that surgical resection was a very strong prog-
nostic factor (Table 3). However, surgical resection had
to be excluded from the nomogram for statistical rea-
sons because all six cases with an incomplete surgical
margin showed metastasis: Odds ratios are calculated as
the probability of metastasis/(1-the probability of metas-
tasis). Therefore, for these cases, the probability of me-
tastasis would be 100%, and the odds ratio would not be
mathematically calculable, as the denominator would
be zero. To overcome this problem, we imposed an
additional clause on the nomogram that the cutoff value
should be added to the total points in the cases of in-
complete surgical resection. Consequently, all the cases
with incomplete resection margin were always metastasis
positive in the dichotomous outcomes.
The performance of the nomogram in predicting di-
chotomous outcomes for metastasis was validated byTable 4 Two way contingency table analysis showing predict
Training set
Observed (N)
Metastasis positive Metastasi
Expected (N) Metastasis positive 28 13
Metastasis free 6 44
Total 34 57
Accuracy % (95% CI) 79.1 (0.69 to 0.86)
Sensitivity % (95% CI) 82.4 (0.69 to 0.92)
Specificity % (95% CI) 77.2 (0.69 to 0.83)
PPV % (95% CI) 68.3 (0.57 to 0.76)
NPV % (95% CI) 88.0 (0.79 to 0.95)
PLR (95% CI) 3.61 (2.21 to 5.36)
NLR (95% CI) 0.23 (0.10 to 0.456)
DOR (95% CI) 15.80 (4.84 to 54.44
Abbreviations: CI confidential interval, PPV positive predictive value, NPV negative pr
DOR diagnostic odds ratio.two-way contingency table analysis (Table 4). The ac-
curacy of the nomogram in predicting dichotomous
outcomes for metastasis was 79.1% (95% CI, 0.69 to
0.86) in the training set and 82.4% (95% CI, 0.63 to
0.92) in the validation set. Although the nomogram
predicted probabilities were lower than the actual
probabilities, dichotomous outcomes showed only a
few false negatives in both sets and high negative pre-
dictive values in the training set (88.0%; 95% CI, 0.79
to 0.95) and validation set (77.8%; 95% CI, 0.60 to
0.87), which implies that the cutoff value was still ef-
fective under underestimated conditions. These results
suggested that the performance of dichotomous out-
comes could be generalizable to other populations.
The introduction of a cutoff value to the nomogram
was advantageous on three counts: to increase clinical
convenience and practicality, to allow the integration
of surgical resection into the nomogram, and to com-
pensate for the underestimation of actual probabilities.
Discussion
To construct a nomogram with better performance, it is
more advantageous to use a large training set and many
prognostic factors with strong correlations to an event.
On the other hand, inclusion of too many predictors
compared to size of training set and overly complicated
parameters of predictors are likely to result in an over-
fitted prediction model. Osteosarcoma is a rare disease
and only a few well-validated prognostic factors for me-
tastasis have been identified, which is likely to make pre-
diction model overfitted. To overcome this and increase
statistical simplicity of the nomogram, we limited the
numbers of predictors used to build the nomogram ac-
cording to the guidelines of Harrell [14]. In addition, weive accuracy of the nomogram
Validation set
Observed (N)
s free Total Metastasis positive Metastasis free Total
41 14 2 16
50 4 14 18
91 18 16 34
82.4 (0.63 to 0.92)
77.8 (0.60 to 0.87)
87.5 (0.67 to 0.98)
87.5 (0.67 to 0.98)
77.8 (0.60 to 0.87)
6.22 (1.83 to 35.63)
0.25 (0.14 to 0.60)
) 24.5 (3.07 to 261.90)
edictive value, PLR positive likelihood ratio, NLR negative likelihood ratio,
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prognosis groups, good or poor. Whether the perform-
ance of the nomogram is reproducible in other popula-
tions is more important than overfitting. We validated
the reproducibility of our nomogram in external valid-
ation set, which was heterogeneous to the training set
with respect to surgeon factor and surgery type (limb
salvage or amputation). The validation results suggested
that our nomogram could be generalizable to other pa-
tient populations, including populations with amputa-
tion rather than limb salvage surgery.
It has been a general consensus that the prognosis of
osteosarcoma with axial and proximal locations is poorer
than that of osteosarcoma with distal locations [5,12].
However, the prognosis of osteosarcoma with proximal
humeral locations is controversial [6,7]. Because the
results of our study were similar to those reported by
Meyers et al., osteosarcomas with proximal humeral
location were classed as good prognosis group in our
nomogram.
Although the effective cutoff range is still uncertain,
tumor size has been reported as a definitive prognostic
factor in osteosarcoma [20,21]. Although the cutoff of
8 cm in maximal tumor diameter was not a prognostic
factor for metastasis in our study, we integrated tumor
size into our nomogram for clinical considerations. We
integrated the effect of large tumor size into tumor site
by defining large tumors exceeding the isthmus of the
affected bone (more than half of the entire length of the
affected bone) as the poor prognosis group, as one
would expect that such a large tumor would show a
poor prognosis. As a result, very large tumors were clas-
sified as poor prognosis group despite their primary
location.
Tumor invasion of the joints with direct penetration
through the articular cartilage are expected to be rare in
osteosarcoma because articular cartilage acts as a strong
barrier to tumor invasion. However, it has been reported
that intracapsular and extrasynovial involvements are
common in osteosarcoma [22,23]. Tumors can extend
under the joint capsule and make contact with the
peripheral margin of the articular cartilage. In the case
of knee joints, tumors can also extend through or
around the osseoustendinous junction of the cruciate
ligaments. We defined intracapsular extension of the
tumor as extension into the intracapsular and extrasyno-
vial structures as well as the penetration through articu-
lar cartilage by tumors. The use of MRI to identify
intracapsular extension is limited because its high sensi-
tivity makes it difficult to distinguish peritumorous
inflammatory changes and edema from the tumor itself,
which results in false-positives [24]. To overcome this,
we confirmed intracapsular extension by MRI and
gross pathology.Complete surgical resection of tumor has also been
regarded as a definitive prognostic factor of osteosar-
coma. However, it may be questionable to assign a cutoff
value for incomplete surgical resection because the
strength of the association between incomplete surgical
resection and metastasis has not been proven quantita-
tively. Inadequate surgical margin (marginal and intrale-
sional margin) had a relative risk of approximately 1.4
for event-free survival or metastasis when compared to
adequate surgical margin (radical and wide margin)
[25,26]. On the basis of these data, the importance of in-
complete surgical resection is likely to be highly under-
estimated if it is not taken into consideration that
residual tumor is not retained in all marginal margins.
In fact, osteosarcoma with incomplete surgical resection
to retain macroscopic residual tumor showed a 5-year
survival rate of only 15% and a relative risk for overall
survival of 3.60 in the multivariate analysis when com-
pared to complete surgical resection, which was higher
than the relative risks of metastasis positive at presenta-
tion [12]. We obtained similar results in our study, al-
though all the incomplete surgical resection cases in our
study were microscopically margin positive.
As survival rates of osteosarcoma increase, the prog-
noses of individual patients become of greater interest.
AJCC and Enneking staging system have been used to
classify prognostic groups after initial assessments. How-
ever, high grade osteosarcoma shows a clinical course so
heterogeneous during treatment that the prognoses of
individual osteosarcomas may widely vary, even if their
initial stages, such as AJCC classification or Enneking
system, are the same. Therefore, a nomogram may be
useful in the management of osteosarcoma to realize
personalized prognoses. Survival rates of osteosarcoma
with metastasis are approximately 20% and early detec-
tion and aggressive metastasectomy should be consid-
ered to increase survival rates of patients with metastasis
[18]. Accordingly, distinguishing patients at high risk for
metastasis according to the nomogram and swift man-
agement of metastatic lesions may comtribute to im-
provement in survival rates forosteosarcoma.
Our nomogram had several limitations. First, our
training set was relatively small and had a deviated com-
position of Asian. In addition, our validation set was
quite small and showed a higher proportions of patients
with metastasis than those of natural populations, as
considerable number of patients with CDF and NED sta-
tus at less than 5 years were excluded from cohort 2 due
to a short follow-up period. The generalizability of our
nomogram should be validated in larger populations
with a natural proportion of patients with metastasis.
Second, our nomogram underestimated actual probabil-
ities presented as percentage. To avoid inaccurate pre-
dictions, dichotomous outcomes should be considered
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the predictors used to construct our nomogram were
confined to clinical factors and could not include mo-
lecular markers. Fourth, our nomogram cannot predict
the time when metastasis occurs because it was based
on logistic regression and not Cox regression. A positive
dichotomous decision for metastasis without any indica-
tion of time of occurrence may be unnerving to patients
and doctors.Conclusions
We have developed a new postoperative nomogram with
high performance and generalizability to predict the prob-
ability of metastasis in Enneking stage IIB extremity osteo-
sarcoma. Development of this nomogram will contribute
greatly to individualized risk assessments for metastasis in
osteosarcoma.
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